This Study DESTROYS What We Thought About Cancer

A 2024 paper in the Journal of Cancer Therapy reported a 35-fold improvement in response rates and 88% measurable symptom improvement in late-stage cancer patients treated under a precision oncology protocol, compared to the standard-of-care benchmarks every major cancer center uses. The data was validated by a third-party actuarial firm. After 25 years of treating cancer patients, I did not expect to see numbers like these in print.

In this video, I walk you through exactly what the study measured, why the actuarial validation matters more than the headline figures, and what it means if you or someone you love is currently sitting in front of an oncologist.

We cover what "standard of care" actually is (and why it is the statistical average, not the ceiling of what is possible), how the study was designed, what a 35x response rate and 88% symptom improvement look like in real patient terms, and the mechanism behind the result: the shift from population-averaged protocols to patient-specific precision oncology based on tumor sequencing and targeted treatment.

Most importantly, I lay out the practical next steps. What to ask your oncologist, when to get a second opinion, how to identify a clinic that actually practices precision oncology, and the honest reality about insurance coverage for this kind of care.

This is not hype. This is one paper, one cohort, and the strongest real-world evidence we have that the biological ceiling many late-stage patients are told to accept is not actually a ceiling.

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Prevention isn’t just about what you avoid — it’s about how you support your body.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493

Transcript

SPEAKER_00 0:08

Over the last 25 years, my team and I have treated patients who were told by other doctors, go home because there's nothing more that can be done. And for 25 years, the assumption behind that sentence was the same old. When you get to stage four, the outcomes are dictated by the biology and the chances are slim. That's really what they want you to think. But in April 2024, we published a paper in the Journal of Cancer Therapy and completely rewrote that assumption. Our team compared a group of late-stage cancer patients treated with very precision personalized protocols, some of the latest technologies from around the world. And we compared that against the standard of care benchmarks, really the one size fits all model that is used in oncology today. We found that the patients who underwent this special treatment of precision oncology, where we look at a thousand plus markers, they had a 35 times better outcome with an 88% of those patients showing measurable improvements in symptoms. That's amazing because these were late-stage cancer patients. So imagine if we saw them sooner. So in this video, I'm gonna walk you through exactly what we found in the study, the treatment that we use to get these results and what it means for you or someone you love that's going through cancer, because your oncologist right now may be saying, Well, there's nothing else you can do. I don't want you to be listening to that because the data actually suggests otherwise. I'm Dr. Dino Prado, founder of NVITA Medical Center. And so before you do anything or change anything, make sure you're working with a doctor. And now let's get started. The first thing we need to understand is this when most people hear standard of care, they assume it means the best medicine available. But that's not what it means at all. Standard of care usually means the accepted default treatment protocol for specific cancer types and stages of cancer based on what has helped other patients in the past, the averages. That matters because cancer is not a disease of averages. Even when two people are told they have the same exact type of cancer, let's say colon cancer, their tumors may behave totally differently when you look at the deep genetic markers. Their immune system may respond totally different. Their tumor microenvironment may be totally different, their inflammatory patterns, very different. Their metabolism is very different, their microbiome is very different. So the idea that we have average protocols is automatically not the best strategy for every person with the same name cancer. And this is where patients get trapped because the system often treats the label, the diagnosis first, and the biology second, meaning the markers, not the detailed markers of the cancer. So here's what happens: it basically says, you have this cancer, so here's your protocol. Instead of asking what are the drivers to your cancer specifically, that's the difference between protocol medicine and precision medicine. And that's why this study that I'm about to go over with you matters so much. Because the benchmark that it's beating, it's not some weak comparison. It is the accepted benchmark used by major cancer centers and systems around the world. So now let's talk about why this paper really deserves attention. Anyone can say, look at this one person who took this and got well. But that's not what gives us the weight of a true good study. What gives us the study weight is that the outcomes were evaluated by a third-party actuarial data and using N of one modeling. So this is different than double blind placebo clinical trials, where you treat large populations all using the same types of treatment for the same types of cancer. These were individually built for each person. That's why we call the work we do precision oncology because it's the targeting that makes all the difference. And that matters because the study was not built on emotions, it was built on measurable outcomes in precision oncology. This is not a randomized controlled trial. When you do a custom protocol for each patient, it's different. In fact, just recently, just in 2026, FDA's just started to open the door to end of one clinical trials because they know the genetic information is way more than standard oncology is doing, and it is the way of the future. And it doesn't mean that every patient will get the same miracle outcome, but they just get far better plans because they have far better testing and custom drug design and delivery. Now let's talk about the real numbers in plain English. The headline number is 35-fold improvement in response rates. It means that the patients were far more likely to have a measurable positive response than what the standard benchmarks predicted. Then there's a second number. I mean, that's the ultimate marker. That's what really matters at the end of the day. So, how's that possible? How do we get such a dramatic improvement? And the answer is simple precision oncology. Standard oncology usually chooses treatment based mainly on where the cancer started and what's the stage. So you got a tumor marker, imaging, and a biopsy. And then you go, okay, we have breast cancer, stage two, three, and four. And then you're put into a national comprehensive network guideline, a protocol. That's standard of care. Precision oncology asks a much deeper question. What is actually driving this tumor? What are the mutations, DNA and RNA? What are the pathways of immunity? Is this a cold cancer? Does it need to become hot? Is the immune system not turned on? What's the immune spatial biology, the immune profiling? See, that changes everything because two patients can both be told they have stage four colon cancer and still have completely different disease biology. This is why using population averages to treat deeply individual biology creates a major problem. The average patient doesn't exist. It never did. And that's why I've said this for years that cancer is not a disease of tissue, but it's a disease of mutations and information and immunity and inflammation. And if you don't gather that information, you don't treat it specifically, the cancer will either resist treatment or return. That's why deeper mapping matters, particularly in late-stage cancers. Early stage cancers can be treated potentially with surgery and then they're over. And the chemo and radiation is basically supportive. It hasn't done anything because the surgery did the work. But when we have people that have difficult cancers or cancers that are mutating, or even they want to get on all the data right away, you want to look at DNA. Think of it as the car that's on the road. We can actually see the vehicle. That's the DNA. The RNA transcriptomics, which are hundreds of markers. So now we have thousands of markers when you combine these two, shows us all the escape routes that that car might take on the freeway and block those. Immune profiling shows us the immune system and exactly what are the players on the field. We can also see the immune spatial biology and we can see all of the gangs around the tumors that are blocking your immune system from doing the work it needs to do. And then custom-build treatments to address every one of those tiny bits of information and get a precision-targeted plan that's not just standard. A lot of people hear the phrase precision and they think that means fringe medicine. It doesn't at all. It just means more data and more targeting. And that's really what people need. That's one of the biggest things that we see with cancer patients is 90% of the patients that we see are on the wrong treatments when we do precision because a lot of the care in standard oncology is guessing. When we replace that with deeper science, you're going to have the data you need, the targets you need, and then you can custom build the medications. That's the other part. On label, off-label, phytotherapeutic, immunotherapy drugs that are custom designed for the patient. So you're working on that biological intelligence and it's personalized for each patient. And that's where you get these far better outcomes. And then there's adaptive monitoring. So while we're treating the patient with precision oncology, we can tell if they're responding or not way before the tumor appears. And that's why this is important. This is a radical change from current oncology that kind of just watches and waits and uses a standard one size fits all for everybody. So when your doctor says there's nothing more you can do, that often doesn't mean there's nothing more biologically possible. It often means there's nothing more they can do that's available for the doctor and the current pathways, sometimes with the current insurance that will cover the care, the current standard regimens, Medicare. Those are all blockades, if you will, to good, great precision targeting. So you want to ask these questions. Did I get the right deep testing? Do I have the right targeting? Or am I just working off of basic pathology reports and basic imaging, right? We need more information than that to really unveil the biology of that unique cancer so we can treat it. And we don't want to wait to do that. The sooner we do that, then we can really help people get the care they need now. So when you're out there looking for a second opinion, one of the biggest mistakes patients make is they wait until nothing works or they stop responding to care because they hope it works, and then they start looking for the second opinion. But my recommendation is get the opinion now because the more data you have, you're gonna eliminate the wrong treatment and you're gonna get the right treatment, which is gonna give you a far greater success of overall health and improvement. That's the reality. That's why this study was very important because it shows that when you do detailed testing on DNA or RNA, you're gonna get better markers and better outcomes. This one study does not overturn all of medicine overnight, but it shows us a great spotlight that we've need to talk about for years that the more data we have and the more personalized the care is, the better chance the patient has. So if someone you know or you're facing cancer, my recommendation is precision really matters. Let it guide the treatment and you can see the difference in the responses. That's how we're hoping to change the world in oncology. Thank you for clicking on the video and share it with somebody who may need it. And you can walk through some of the other videos that we've made that go through other combination care models that can help you, like supplements or other evidence-based things in human cancer trials that you can take a look at with patients. I hope you found this video helpful and may the Lord bless you on your journey to healing.